MannKind | MNKD - Debt


MannKind reported $330.96M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Adma Biologics USD 204.41M 121.28M Mar/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Eli Lilly USD 43.37B 867M Mar/2026
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Insmed USD 725.8M 1.82M Jun/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
MacroGenics USD 36.51M 500K Mar/2026
MannKind USD 330.96M 36.48M Mar/2026
Merck USD 49.12B 222M Mar/2026
Minerva Neurosciences USD 0 0 Sep/2024
Novavax USD 233.31M 4.23M Sep/2024
Novo Nordisk DKK 146.38B 27.66B Mar/2026
Pfizer USD 63.19B 536M Jun/2026
Sanofi EUR 23.58B 3.56B Jun/2026
Xencor USD 175.16M 12.58M Mar/2026